CTEng Career Placement

Graduates of CTEng currently hold positions at successful companies, including multi-national and mid/large-sized companies as well as start-ups.

  • Biotech – Amniox Medical, Bayer, CR Bard, WL Gore, Dexcom, MiMedx Group, MedShape, AxoGen, Gatan, Edwards Lifesciences
  • Pharma – Biogen, Capricor, Takeda Pharmaceuticals,
  • Government Science –CDC
  • Regulatory Science –  FDA
  • Scientific Writing – RA Capital, Project Lead the Way
  • Entrepreneurship – Spectropath, Wyss Institute
  • Consulting – Keystone Strategy
  • Academia – Harvard University, Duke University, MIT, EPFL

CTEng Alumni Profiles

Andres Bratt-Leal, Ph.D.

In Dr. Todd McDevitt's lab, my research focused on directing stem cell behavior within a three-dimensonal model system of differentiation. By incorporating biomaterial microparticles within aggregates of stem cells, I was able to deliver growth factors in a spatially controlled way that makes tissue engineering of early developmental structures easier. After graduating from Georgia Tech, I began a postdoctoral fellowship at The Scripps Research Institute with Dr. Jeanne Loring studying dopaminergic differentiation from induced pluripotent stem cells made from the skin of Parkinson's disease patients. Today, I am Senior Scientist at the Parkinson's Association where, together with Dr. Loring, I lead a team working to develop a stem cell-based therapy for Parkinson's disease. I'm grateful for the support provided by the tissue engineering training grant and for the opportunities to expand my network both in industry and academia.  

Ashley Brown, Ph.D.

As a Cell and Tissue Engineering Trainee, I worked with Dr. Thomas Barker at the Georgia Institute of Technology, and my doctoral work centered on understanding the role of the extracellular matrix in wound healing and fibrotic progression, specifically focusing on the role of substrate elasticity and integrin specific interactions in modulating pulmonary epithelial to mesenchymal transitions.  Following the completion of my PhD, I was an American Heart Association postdoctoral fellow under the mentorship of Drs. Andrew Lyon and Thomas Barker.  The goal of my postdoctoral work centered on developing novel fibrin-engaging materials for use as hemostatic materials.  This work resulted in the fabrication of platelet-like particles (PLPs) comprised of innovative ultra-low cross-linked pNIPAM-based microgels, which specifically target wound sites through molecularly evolved fibrin-recognition sites, decrease bleeding times, and are capable of inducing clot contraction.  Currently I am an Assistant Professor in the Joint Department of Biomedical Engineering at North Carolina State University and the University of North Carolina at Chapel Hill.  My group is working on a variety of projects that utilize microgel constructs to 1) better understand cellular mechanotransduction mechanisms in wound healing and 2) interact with the body’s native repair processes to improve wound healing outcomes.


Peter Crapo, Ph.D.

As a graduate student, Peter Crapo researched biomaterials applications in cardiovascular tissue engineering. His research projects included engineering and characterizing small diameter vascular constructs based on a biodegradable elastomer and myocardium using small intestinal submucosa as a substrate. He is currently a Senior Scientist with C. R. Bard, Inc., working in early stage development and evaluation of medical devices for soft tissue repair and hemostasis. His previous work with Bard has focused on the development of biologic grafts for hernia and soft tissue repair applications. Peter has 16 peer-reviewed publications and also serves as a reviewer for a number of journals in the fields of biomedical engineering and biomaterials.


Jeremy Lim, Ph.D.

Jeremy graduated with a PhD from Georgia Tech and Emory University’s Department of Biomedical Engineering in 2012. The objective of his research with Johnna Temenoff, PhD was to develop glycosaminoglycan-based materials to promote chondrogenic differentiation of mesenchymal stem cells. By controlling the presentation and sulfation pattern of chondroitin sulfate, Jeremy designed a platform of 2D surfaces, small-scale particles, and 3D hydrogels to regulate cell-cell, cell-matrix, and growth factor-matrix interactions within these various materials. As part of the CTEng training program, Jeremy also participated in an industrial internship at MedShape, Inc. in Atlanta, GA, where he was responsible for developing porous shape memory materials to enhance tissue integration with MedShape’s portfolio of fixation devices.

Jeremy is currently a Senior Biomedical Engineer with MiMedx Group, Inc. in Marietta, GA. Jeremy investigates the various mechanisms by which MiMedx PURION® Processed human amniotic membrane allografts modulate inflammation, reduce scar tissue formation, and enhance soft tissue healing, including through angiogenesis, stem cell recruitment, and modulation of stem cell activity. 


Ivana Parker, Ph.D.

Ivana worked to investigate the role of cathepsins, potent elastases and collagenases, in the progression of HIV - related cardiovascular disease with Dr. Manu Platt. Her research investigated the effects of hemodynamic environment and  HIV-proteins or antiretroviral regiment on cathepsin activity in arterial cells. This work was performed using an HIV-tg mouse model, and verified using human endothelial cells systems and a shear stress bioreactor. Her work demonstrated that the upregulation of cathepsins in vivo and in vitro is caused by a synergism between pro-atherogenic shear stress and HIV-1 proteins and elucidated pathways that are activated by HIV-1 Tat and pro-atherogenic shear stress - leading to cathepsin-mediated ECM degradation. 

She recently received the ASM/CDC Program in Infection Disease and Public Health Microbiology Postdoctoral Research Fellowship where she will be working  at the National Center for Preparedness, Detection, and Control of Infectious Diseases (NCPDCID). Her work there will aim to improve the monitoring of HIV incidence, the number of new infections, by developing bioplex assays, and identifying biomarkers for accurate recent infection detection. 


Crystal Simon, PhD.

Crystal earned her PhD in 2008 after studying spinal cord injury in Dr. Michelle LaPlaca's laboratory.  Her expertise in neural trauma and biomaterials uniquely positioned her as a Product Development Engineer at AxoGen, Inc., a company focused on providing solutions for patients who suffer from peripheral nerve injuries.  The Biomedical Engineering curriculum gave Crystal the skillsets to collaborate with engineers, clinicians, and other cross-functional teams, as well as expertise in leading projects from concept to completion.  Within less than two years of graduation, Crystal was able to lead the development efforts and product launch on two implantable devices for nerve repair, specifically the AxoGuard(R) Nerve Connector and the AxoGuard(R) Nerve Protector.  

Crystal has been a leader in the medical device industry, holding product development and marketing positions at AxoGen, OmniGuide, and Intuitive Surgical.  As of 2015, Crystal leads Medical Affairs and Professional Education at AxoGen, Inc.